HIV Point of Care Diagnostics Pipeline
From Treatment Action Group and HIV i-Base
Table of Contents
Access to appropriate care and treatment is dependent on first diagnosing HIV and then managing the infection both on and off treatment.
For anyone over 18 months old, an initial HIV diagnosis is usually made using a rapid antibody test - of which there is quite an array of choices that are cheap, accurate, and easy to use within decentralized care.
CD4 tests are recommended for staging and monitoring the disease prior to initiating antiretroviral treatment -- and for monitoring immune response to treatment, allowing opportunistic infection prophylaxis to be removed if higher CD4 counts are achieved -- and viral load tests once treatment is started.
Because of passive transplacental transfer of maternal antibodies that can persist for up to 18 months antibody tests cannot be used for the accurate diagnosis of infants. So virological testing needs to be performed to determine an infant's HIV status and enable immediate initiation of antiretroviral therapy (ART).
Although there are currently many options available for CD4 and virological testing, they are expensive and require sophisticated, centralized laboratories and trained technicians. To improve access to diagnostics in resource-limited settings and to make them affordable, they must be delivered as close as possible to the patient. A recent technical report from UNITAID describes a "diagnostic landscape" with high volume testing performed in centralized facilities ("super labs") where feasible, and, most importantly, a drive towards decentralized point of care (POC) testing in harder to reach populations.1
This chapter looks at the latter and describes promising POC technologies in the pipeline for CD4, viral load and early infant diagnosis (EID). These tests may be commercially available within the next couple of years. Many of the test sponsors appear to believe that their products will launch commercially next year. If their predictions come true then 2012 will be a bumper year for HIV POC diagnostics. The authors cannot guarantee that this bonanza will occur in 2012.
In order for a diagnostic test to be useful within a decentralized setting it should meet the WHO ASSURED criteria for the ideal rapid test, which is as follows:
A = affordable
S = sensitive
S = specific
U = user friendly (simple to perform in a few steps with minimal training)
R = robust and rapid (results available in less than 30 minutes)
E = equipment free
D = deliverable to those who need the test
The CD4 Initiative, based at Imperial College in London, was set up in 2005 to develop simple, instrument-free CD4 point of care tests designed specifically for rural areas in resource-limited settings.2
They began with a target product profile with a set of specifications that elaborate on the ASSURED criteria.
- Simple and robust
- Semi-quantitative, minimum cut off of 250 cells/mm3
- Stable at 40°C for 12 months
- Quality assurance material to check correct functioning of test
- Use of finger-prick blood/other non-venous blood sample
- Simple to perform, few steps and <2 hours training required
- <30 minutes from patient to result
- Simple read out
- All-in-one kit
- 25 tests performed/person/day
- Target price around $2 per test
- Customer capital outlay (if any) <$1,000
- Safe solution for infectious waste materials
In partnership with Zyomyx they have developed a fully quantative CD4 counter, that can be read visually without an electronic reader, much like a thermometer. It consists of a disposable cartridge with a mechanical spinner that requires no power supply. The test can measure an absolute CD4 count without complex instruments. Clinical trials are expected in 2011. If the results are positive, the test could begin to become available by 2012, according to Zyomyx.3
The Burnet Institute -- who also worked on their prototype within the CD4 Initiative -- is continuing to develop a rapid CD4 test in collaboration with the Rush University Medical Center and Duke University.4
This test is semi-quantative and will give a read out showing whether someone's CD4 count is above or below a predetermined threshold -- e.g., 350 cells/mm3. The user then can make a treat/don't treat decision. Burnet is developing a reader for the device in collaboration with Axxin Ltd.
Clinical trials are planned in 2011 in the United States and Malawi. The further development and the launch of this test will depend on trial results and project funding.
Daktari Diagnostics is in late stage development of a portable CD4 cell counter. The device is a portable battery run instrument. Each CD4 test consists of a disposable plastic card, which is inserted into the instrument. The test measures absolute CD4 count.5
Validation studies in four African countries are expected to be underway this year. Follow-on studies in additional countries are also planned. The commercial launch is expected at the end of 2011.
MBio Diagnostics is developing a system that uses disposable cartridges and a simple reader instrument. It provides an absolute CD4 count.6
Field-testing in southern Africa is scheduled for later this year.
No comments have been made.